Literature DB >> 23048106

The contributions of prevention and treatment to the decline in cardiovascular mortality: lessons from a forty-year debate.

David S Jones1, Jeremy A Greene.   

Abstract

Mortality from coronary heart disease in the United States has fallen 60 percent from its peak in the mid-1960s. Cardiologists and epidemiologists have debated whether this decline reflects better control of risk factors, including lifestyle interventions to reduce smoking or intake of dietary fats, or the power of medical interventions, including defibrillators and therapeutics such as statins. Attempts to resolve this debate and guide health policy have generated sophisticated data sets and techniques for modeling cardiovascular mortality. Neither effort has provided specific guidance for health policy. Historical analysis of the debate over the causes of the decline, concomitant with development of cardiovascular modeling, offers valuable policy lessons about tensions among medical and public health strategies, the changing meanings of disease prevention, and the ability of evidence-based research and models to guide health policy. Policy makers must learn to open up the "black box" of epidemiological models-and of their own decision-making processes-to produce the best evidence-informed policy.

Entities:  

Mesh:

Year:  2012        PMID: 23048106     DOI: 10.1377/hlthaff.2011.0639

Source DB:  PubMed          Journal:  Health Aff (Millwood)        ISSN: 0278-2715            Impact factor:   6.301


  11 in total

Review 1.  Molecular sources of residual cardiovascular risk, clinical signals, and innovative solutions: relationship with subclinical disease, undertreatment, and poor adherence: implications of new evidence upon optimizing cardiovascular patient outcomes.

Authors:  Richard Kones
Journal:  Vasc Health Risk Manag       Date:  2013-10-21

2.  Cost-effectiveness of Evolocumab Therapy for Reducing Cardiovascular Events in Patients With Atherosclerotic Cardiovascular Disease.

Authors:  Gregg C Fonarow; Anthony C Keech; Terje R Pedersen; Robert P Giugliano; Peter S Sever; Peter Lindgren; Ben van Hout; Guillermo Villa; Yi Qian; Ransi Somaratne; Marc S Sabatine
Journal:  JAMA Cardiol       Date:  2017-10-01       Impact factor: 14.676

Review 3.  Decline in Cardiovascular Mortality: Possible Causes and Implications.

Authors:  George A Mensah; Gina S Wei; Paul D Sorlie; Lawrence J Fine; Yves Rosenberg; Peter G Kaufmann; Michael E Mussolino; Lucy L Hsu; Ebyan Addou; Michael M Engelgau; David Gordon
Journal:  Circ Res       Date:  2017-01-20       Impact factor: 17.367

4.  Trends in Cardiovascular Disease Mortality Among Persons With HIV in New York City, 2001-2012.

Authors:  David B Hanna; Chitra Ramaswamy; Robert C Kaplan; Jorge R Kizer; Kathryn Anastos; Demetre Daskalakis; Regina Zimmerman; Sarah L Braunstein
Journal:  Clin Infect Dis       Date:  2016-07-20       Impact factor: 9.079

5.  The decline and rise of coronary heart disease: understanding public health catastrophism.

Authors:  David S Jones; Jeremy A Greene
Journal:  Am J Public Health       Date:  2013-05-16       Impact factor: 9.308

6.  More americans living longer with cardiovascular disease will increase costs while lowering quality of life.

Authors:  Ankur Pandya; Thomas A Gaziano; Milton C Weinstein; David Cutler
Journal:  Health Aff (Millwood)       Date:  2013-10       Impact factor: 6.301

7.  Falling Coronary Heart Disease Rates: A Better Explanation?

Authors:  Russell V Luepker
Journal:  Circulation       Date:  2015-11-18       Impact factor: 29.690

8.  Changes in Cardiovascular Health in the United States, 2003-2011.

Authors:  Courtney S Pilkerton; Sarah S Singh; Thomas K Bias; Stephanie J Frisbee
Journal:  J Am Heart Assoc       Date:  2015-09-22       Impact factor: 5.501

9.  A two-decade comparison of prevalence of dementia in individuals aged 65 years and older from three geographical areas of England: results of the Cognitive Function and Ageing Study I and II.

Authors:  Fiona E Matthews; Antony Arthur; Linda E Barnes; John Bond; Carol Jagger; Louise Robinson; Carol Brayne
Journal:  Lancet       Date:  2013-07-17       Impact factor: 79.321

10.  Cost-Effectiveness of LDL-C Lowering With Evolocumab in Patients With High Cardiovascular Risk in the United States.

Authors:  Shravanthi R Gandra; Guillermo Villa; Gregg C Fonarow; Mickael Lothgren; Peter Lindgren; Ransi Somaratne; Ben van Hout
Journal:  Clin Cardiol       Date:  2016-04-19       Impact factor: 2.882

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.